Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge

Parkinsonism and Related Disorders

Volumn 18, Issue 5, 2012, Pages 514-519

  Evans, Andrew H ^a,b   Farrell, Michael J ^c   Gibson, Stephen J ^b,d   Helme, Robert D ^e   Lim, Shen Yang ^a,f  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^e EPWORTH HOSPITAL   (Australia)

^f UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Affect; Dyskinesia; Non motor; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AFFECT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DISSOCIATION; DRUG RECHALLENGE; DRUG RESPONSE; DYSKINESIA; EVOKED MUSCLE RESPONSE; HUMAN; MOTOR PERFORMANCE; NEGATIVE AFFECT; PARKINSON DISEASE; PATIENT ASSESSMENT; PATIENT CODING; POSITIVE AFFECT; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PURDUE PEGBOARD TEST; REBOUND; REGRESSION ANALYSIS; TREATMENT RESPONSE;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MOOD DISORDERS; PARKINSON DISEASE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84861190566     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.01.020     Document Type: Article

References (30)

1. Calabresi P., Di F.M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010 Nov, 9(11):1106-1117.
2. Pavese N., Evans A.H., Tai Y.F., Hotton G., Brooks D.J., Lees A.J., et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006 Nov 14, 67(9):1612-1617.
3. Maricle R.A., Valentine R.J., Carter J., Nutt J.G. Mood response to levodopa infusion in early Parkinson's disease. Neurology 1998 Jun, 50(6):1890-1892.
4. Menza M.A., Sage J., Marshall E., Cody R., Duvoisin R. Mood changes and 'on-off' phenomena in Parkinson's disease. Mov Disord 1990, 5(2):148-151.
5. Watson D., Clark L.A., Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988, 54(6):1063-1070.
6. Crawford J.R., Henry J.D. The positive and negative affect schedule (PANAS): construct validity, measurement properties and normative data in a large non-clinical sample. Br J Clin Psychol 2004 Sep, 43(Part 3):245-265.
7. Whittle S., Allen N.B., Fornito A., Lubman D.I., Simmons J.G., Pantelis C., et al. Variations in cortical folding patterns are related to individual differences in temperament. Psychiatry Res 2009 Apr 30, 172(1):68-74.
8. Smith K.S., Berridge K.C., Aldridge J.W. Disentangling pleasure from incentive salience and learning signals in brain reward circuitry. Proc Natl Acad Sci U S A 2011 July 5, 108(27):E255-E264.
9. Guigoni C., Li Q., Aubert I., Dovero S., Bioulac B.H., Bloch B., et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 2005 Feb 23, 25(8):2102-2107.
10. Lim S.Y., Farrell M.J., Gibson S.J., Helme R.D., Lang A.E., Evans A.H. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?. Mov Disord 2008 Sep 15, 23(12):1689-1695.
11. TIFFIN J., ASHER E.J. The purdue pegboard; norms and studies of reliability and validity. J Appl Psychol 1948 Jun, 32(3):234-247.
12. Vingerhoets G., Verleden S., Santens P., Miatton M., De R.J. Predictors of cognitive impairment in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2003 Jun, 74(6):793-796.
13. Katzenschlager R., Hughes A., Evans A., Manson A.J., Hoffman M., Swinn L., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005 Feb, 20(2):151-157.
14. Stacy M., Bowron A., Guttman M., Hauser R., Hughes K., Larsen J.P., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005 Jun, 20(6):726-733.
15. Evans A.H., Lawrence A.D., Potts J., Appel S., Lees A.J. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005 Nov 22, 65(10):1570-1574.
16. Kempster P.A., Frankel J.P., Stern G.M., Lees A.J. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990 Nov, 53(11):1004-1007.
17. Nutt J.G., Gancher S.T., Woodward W.R. Does an inhibitory action of levodopa contribute to motor fluctuations?. Neurology 1988 Oct, 38(10):1553-1557.
18. Larsen J.T., McGraw A.P., Cacioppo J.T. Can people feel happy and sad at the same time?. J Pers Soc Psychol 2001 Oct, 81(4):684-696.
19. Davidson R.J. Affective neuroscience and psychophysiology: toward a synthesis. Psychophysiology 2003 Sep, 40(5):655-665.
20. Evans A.H., Lawrence A.D., Lees A.J. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009 Mar, 80(3):267-272.
21. Evans A.H., Lawrence A.D., Cresswell S.A., Katzenschlager R., Lees A.J. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Mov Disord 2010 May 15, 25(7):867-876.
22. Schneider F., Habel U., Volkmann J., Regel S., Kornischka J., Sturm V., et al. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry 2003 Mar, 60(3):296-302.
23. Kienast T., Siessmeier T., Wrase J., Braus D.F., Smolka M.N., Buchholz H.G., et al. Ratio of dopamine synthesis capacity to D2 receptor availability in ventral striatum correlates with central processing of affective stimuli. Eur J Nucl Med Mol Imaging 2008 Jun, 35(6):1147-1158.
24. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006 May, 59(5):852-858.
25. Li Y., Kolb B., Robinson T.E. The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudate-putamen. Neuropsychopharmacology 2003 Jun, 28(6):1082-1085.
26. Clissold B.G., McColl C.D., Reardon K.R., Shiff M., Kempster P.A. Longitudinal study of the motor response to levodopa in Parkinson's disease. Mov Disord 2006 Dec, 21(12):2116-2121.
27. Nutt J.G., Carter J.H., Lea E.S., Sexton G.J. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002 Jun, 51(6):686-693.
28. Damiano A.M., McGrath M.M., Willian M.K., Snyder C.F., LeWitt P.A., Reyes P.F., et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 2000 Feb, 9(1):87-100.
29. Silveira-Moriyama L., Evans A.H., Katzenschlager R., Lees A.J. Punding and dyskinesias. Mov Disord 2006 Dec, 21(12):2214-2217.
30. Lee J.Y., Kim J.M., Kim J.W., Cho J., Lee W.Y., Kim H.J., et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010 Mar, 16(3):202-207.